GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NM-6603 overview
NM-6603 is under development for the treatment of triple negative breast cancer, lung cancer, liver cancer, pancreatic cancer, cervical cancer, melanoma and colorectal cancer. It is administered through oral route in the form of capsule. It acts by targeting retinoic acid receptor (RXR) alpha.
Nucmito overview
Nucmito is a biopharmaceutical company which focuses on research and development of nuclear receptor small molecule drugs used for the treatment of solid tumors. The company is headquartered in Xiamen, Fujian, China.
For a complete picture of NM-6603’s drug-specific PTSR and LoA scores, buy the report here.
From 
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.